Sentences with phrase «reported effects of those actions»

We developed a findings template that drew upon Spillane «s conceptualization of leadership practice.109 The template enabled us to construct descriptions of (1) sources of leadership linked to (2) specific actions and (3) goals in (4) specific contexts, along with (5) the co-participants in those situations, (6) the reported effects of those actions, and (7) the reported factors influencing those leadership variables.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

And the Harvard Business Review has reported significant scientific evidence that sleep deprivation, because of its effects on decision - making and thought process, can actually cause or facilitate unethical actions.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Based on a high - level audit of all reports of sexual harassment or violence for three academic years from 2012 - 2013 through 2014 - 2015, Pepper found that the University's student conduct processes were wholly inadequate to consistently provide a prompt and equitable response under Title IX, that Baylor failed to consistently support complainants through the provision of interim measures, and that in some cases, the University failed to take action to identify and eliminate a potential hostile environment, prevent its recurrence, or address its effects for individual complainants or the broader campus community.

HIV Medicine DOI: 10.1111/j.1468-1293.2011.00918.x IBFAN - Asia Position Statement on HIV and Infant Feeding, 13 October 2008 South African Tshwane Declaration on breastfeeding, S Afr J Clin Nutr 2011; 24 (4) UNAIDS 2010, Strategy Getting to Zero, UNAIDS Strategy 2011 — 2015 UNAIDS 2010, Agenda for Accelerated Country Action for Women, Girls, Gender Equality and HIV, 2010 - 2014 UNAIDS 2011, Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011 - 2015 UNAIDS 2011 Press Release, 9 June, World leaders launch plan to eliminate new HIV infections among children by 2015 UNICEF Convention on the Rights of the Child UNICEF 2010, Facts for Life UNICEF 2011, Programming Guide, Infant and Young Child Feeding, 26 May 2011 WHO / UNICEF 2003, Global strategy for infant and young child feeding WHO 2007, Evidence on the long - term effects of breastfeeding: systematic reviews and meta - analysis WHO, UNAIDS, UNICEF 2009, Towards universal access: scaling up priority HIV / AIDS interventions in the health sector: progress report 2009 WHO 2009, Women and health, Today's evidence tomorrow's agenda WHO 2009, Acceptable medical reasons for use of breast - milk substitutes WHO 2009, Rapid advice: use of antiretroviral drugs for treating pregnant womenand preventing HIV Infection in infants WHO 2009, Rapid advice: revised WHO principles and recommendations on infant feeding in the context of HIV WHO 2010, Priority Interventions — HIV / AIDS prevention, treatment and care in the health sector WHO 2010, Guidelines on HIV and infant feeding: Principles and recomendations for infant feeding in the context of HIV and a summary of evidence WHO 2010, Annexure 7b to Guidelines on HIV and infant feeding.

The International Code of Marketing of Breast - Milk Substitutes (2008) Frequently asked questions (updated version 2008) The International Code of Marketing of Breast - Milk Substitutes (1998) Summary of action taken by WHO Member States and other interested parties, 1994 - 1998 The International Code of Marketing of Breast - Milk Substitutes (1996) A common review and evaluation framework The International Code of Marketing of Breast - Milk Substitutes (1992) Survey of national legislation and other measures adopted (1981 - 1991) Review and evaluation of national action taken to give effect to the International Code of Marketing of Breast - Milk Substitutes (1991) Report of a technical meeting, The Hague, 30 September - 3 October 1991 The International Code of Marketing of Breast - Milk Substitutes (1990) Synthesis of reports on action taken (1981 - 1990) International Code of Marketing of Breast - Milk Substitutes (1981) Infant formula and related trade issues in the context of the international code [pdf 18kb] The WHO briefing note on «Follow - Up Formula in the Context of the International Code of Marketing of Breast - milk Substitutes» is presently being considered for revision by the World Health Organization pending review of new and emerging information on the subject.

From a forest management perspective, the report notes that «management actions can either mitigate or exacerbate the effects of drought.»

The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»

The study, published in Cell Reports, discovered that the action of a gene called FOXO is inhibited in flies given a high sugar diet in early life, causing long - term effects.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

We reported this to the Food Standards Agency, who have taken action to notify Cow & Gate of labelling requirements and issued the following statement: In light of advice from the Scientific Advisory Committee on Nutrition on the adverse effects of trans fats on the risk of coronary heart disease, the Agency welcomes the voluntary action by the UK food industry to reduce the levels of artificial trans fats in our foods.

The negative effects seem to lie in the capacity of some foods / nutrients to stimulate proliferative pathways that in turn stimulate development of acne — suspect foods include those with a high glycaemic load and milk.11, 43, 44 Other evidence comes from several studies reporting that the prevalence of acne varies significantly between different populations and is substantially lower in non-Westernized populations that follow traditional diets, 45 a common factor among these traditional diets being a low glycaemic load.46 Various studies have provided evidence that high - glycaemic - load diets are implicated in the aetiology of acne through their capacity to stimulate insulin, androgen bioavailability and insulin - like growth factor - 1 (IGF - 1) activity, whereas the beneficial effects of low - glycaemic - load diets, apart from weight and blood glucose levels, also include improved skin quality.44 The clinical and experimental evidence does in fact suggest ways in which insulin can increase androgen production and affect via induction of steroidogenic enzymes, 47 the secretion by the pituitary gland of gonadotropin - releasing hormone and the production of sex hormone - binding globulin.48 Insulin is also able to reduce serum levels of IGF - binding protein - 1 increasing the effect of IGF - 1.49 These insulin - mediated actions can therefore influence diverse factors that underlie the development of acne such as:

THQ triggering Red Faction: Armageddon Obsidian unearthing Dungeon Siege 3 iPhone 4 introduces gyroscope gaming E3 to draw 41,000 + Elemental: War of Magic raging August 24 Marvelous gives up on original titles Dragon Age anime - ting in 2011 Yakuza 4 mobbing North America, Europe, spring 2011 Downloadable Games for Windows to arrive day - and - date Red Dead Redemption sells 5M, GTAIV hits 17M Power Gig signs Eric Clapton, padless drum controller DSi XL feeling midnight blue July 11 DJ Hero 2 spinning Dr. Dre, Metallica, Lady Gaga Mortal Kombat Rebirth teaser touts star power MAG expanding June 22 MTV Games, Gibson resolve patent tussle Neversoft staffing up for «action shooter» Violent games mostly «harmless» - Study Enslaved being freed in October Hulu Xbox 360 - bound - Report Telltale adapting Back to the Future, Jurassic Park Sony launches 3D PS3 games tomorrow XCOM to land in 2011, Mafia II tops 2K E3 lineup Square Enix preps new portable Kingdom Hearts, Parasite Eve Portal 2 closed until 2011 FIFA 11 kicking off this autumn Atlus preps Trine 2, PSP Knights in the Nightmare Mass Effect 2 Overlord DLC landing June 15 NBA Jam drives the lane in October Quick Hit scores NFL license MotorStorm Apocalypse revs up PS3 next year Dreamcast to be reborn on XBL, PSN Mortal Kombat set for 360, PS3 in 2011 «Real» keyboard, guitars debut in Rock Band 3 Space Invaders, Necromachina lead Square Enix digital lineup Bad Company 2 Onslaught begins June 22 Rock Band 3 peripherals priced, bundled Fraction of gamers aware of Move, Natal - Nielsen Living Statue, Obstacle Course revealed for Project Natal - Report Civilization V rises in September

Spurred by a government report warning about the effects of overeating and inactivity among children, education and health officials formed Action for Healthy Kids, a group that works with schools to promote more healthful lifestyles for youngsters.

A separate report on implementation of Title I up to 2005 found similarly slim effect, with by far the most common «restructuring» action being hiring a new principal.

Helping Schools Promote Fitness, Healthful Diets Spurred by a government report warning about the effects of overeating and inactivity among children, education and health officials formed Action for Healthy Kids, a group that works with schools to promote more healthful lifestyles for youngsters.

Such a defense, if established, shall be a bar to the action or proceeding, notwithstanding that (A) after such act or omission, such interpretation or opinion is modified or rescinded or is determined by judicial authority to be invalid or of no legal effect, or (B) after publishing or filing the description and annual reports, such publication or filing is determined by judicial authority not to be in conformity with the requirements of this title.

Following are the things that can effect changes on your scores: • Consistent and constant late payments • Increased or reduced credit limits • Higher credit card balances • Higher HELOC (Home Equity Line of Credit) balance • Closing revolving accounts • Recent credit inquiries made In the same way, any new practice you start in managing your credit takes effect and influence your credit scores within 30 to 60 days; due to the lag time between the action you take against the period it takes the creditor to report the action to the agencies who handle credit reports.

If your credit information is having a negative effect on your insurance price then under the Fair Credit Reporting Act insurers are required to you a notice of adverse action.

Meclizine is an antihistamine and has antiemetic properties.10 In the past 3 years, it has increased in popularity as a treatment for vestibular disease.10 Its use as a treatment for motion sickness in dogs is considered off label, and its exact mechanism of action for the prevention of motion sickness is not understood.10 If used, the recommendation is to administer it 30 to 60 minutes before travel.10 Sedation has been reported as the most common side effect.10

As the Boston Globe reported on April 16, 2014, «Nations need to take aggressive action in the next 15 years to cut carbon emissions, in order to forestall the worst effects of global warming.»

Denial Is Not A River In Egypt While the fossil fuel industry continues to hawk its wares in total denial of the devastating global effects of its actions, the new International Panel on Climate Change (IPCC) Fifth Assessment Report confirms the necessity for immediate and sustained action.

Costs are defined in a variety of ways and under a variety of assumptions that affect their value ► Cost types include: ► administrative costs of planning, management, monitoring, audits, accounting, reporting, clerical activities, etc. associated with a project or program; ► damage costs to ecosystems, economies and people due to negative effects from climate change; ► implementation costs of changing existing rules and regulation, capacity building efforts, information, training and education, etc. to put a policy into place; ► private costs are carried by individuals, companies or other private entities that undertake the action, where ► social costs include additionally the external costs on the environment and on society as a whole.

The «highly conservative» U.N. Intergovernmental Panel on Climate Change found, in its most recent report, that we're already feeling the effects of climate change, and that, barring significant action to reduce emissions, they're only going to get worse.

While the fossil fuel industry continues to hawk its wares in total denial of the devastating global effects of its actions, the new International Panel on Climate Change (IPCC) Fifth Assessment Report confirms the necessity for immediate and sustained action.

Predicting a global average of 2.5 degrees C rise expected by 2038 with «major economic consequences» and a 5 degree C rise by 2067 with «globally catastrophic effects,» the report concludes that there is «no leeway» regarding the «time for action.»

The new report underscores the urgency of the task before policymakers around the world — take potentially expensive actions now to reduce emissions in order to avoid the worst effects of global warming years down the road.

If you happen to have a citation handy to any survey or study reporting the prevalence of this belief, it would be useful because I am collecting instances of mistaken beliefs and their effects on misdirecting people's actions on GHG mitigation.

The report says that «spreading information on (intended) collective action may potentially have an adverse effect on the economic situation of the defendant whose liability has not yet been established.»

Similarly, to view Call to Action # 28 as hived off from other Calls to Action in the TRC Report also could have the effect of isolating legal education from other integrated responses to the TRC (perhaps, for example, involving collaborative initiatives between courts, law societies and law schools).

The report also provides action steps that organizations can take to reduce the effects of gender stereotyping in the workplace.

The findings of the report «highlight the cumulative effect of government policies and individual action».

This 2002 report (PDF: 127 KB) is the result of the Mold Working Group of the Risk Management Committee, formed to evaluate the available information on mold and develop recommendations for actions which might be taken by the National Association to assist members of the National Association in addressing the issues raised by mold as it effects the real estate industry.

Talking to the lender who holds the mortgage note on the property might provide specific answers as the possible courses of action available to the borrower, as well as to the effects those actions might have on that person's credit report.